secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keenova Therapeutics plc (—)
CIK:        0001567892
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001567892-24-000015
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mallinckrodt Q1 net sales up 10.2% to $467.8M; net loss improves 73.8%
----------------------------------------------------------------------

- Net sales of $467.8M, up 10.2% YoY on a reported and constant currency basis.
- Net loss of $65.4M, a 73.8% improvement from $249.3M in prior year quarter.
- Adjusted EBITDA $144.9M, up 17.3% YoY from $123.5M.
- Acthar Gel net sales $102.8M (+25.4%), Terlivaz $6.0M; Specialty Generics +22.0%.
- Full year guidance reaffirmed; SelfJect launch expected in Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567892/000156789224000015/0001567892-24-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567892/000156789224000015/mnk-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001567892-24-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer